Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nevirapine
Drug ID BADD_D01557
Description A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Indications and Usage For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
Marketing Status Prescription; Discontinued
ATC Code J05AG01
DrugBank ID DB00238
KEGG ID D00435
MeSH ID D019829
PubChem ID 4463
TTD Drug ID D0O2EM
NDC Product Code 42571-131; 68554-0044; 65862-932; 31722-505; 0781-5893; 0597-0123; 65162-209; 64380-709; 33342-004; 65862-027; 0378-4050; 0378-4890; 70159-002; 65862-057; 53104-7546; 65862-933; 33342-238; 64220-102; 0597-0047
Synonyms Nevirapine | Nevirapine Hemihydrate | Hemihydrate, Nevirapine | Viramune | BI-RG-587 | BI RG 587 | BIRG587
Chemical Information
Molecular Formula C15H14N4O
CAS Registry Number 129618-40-2
SMILES CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.0030.012155%Not Available
Spina bifida03.10.02.005; 17.19.01.0040.003171%Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.0200.042543%
Stillbirth18.01.02.002; 08.04.01.0060.004756%Not Available
Surgery25.01.02.003--Not Available
Swelling face23.04.01.018; 10.01.05.0180.012155%Not Available
Tachycardia02.03.02.0070.018233%Not Available
Tendon disorder15.07.01.0020.048621%Not Available
Thrombocytopenia01.08.01.002--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.006342%
Tuberculosis11.04.01.0060.006342%Not Available
Ulcer08.03.06.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Ventricular fibrillation02.03.04.0080.003171%
Vertical infection transmission11.07.02.005--Not Available
Vomiting07.01.07.003--
Fat redistribution14.08.04.002--Not Available
Lipodystrophy acquired23.07.01.003; 14.08.04.0080.012155%Not Available
Blood phosphorus decreased13.11.01.015--Not Available
T-lymphocyte count decreased13.01.06.0490.018233%Not Available
Conjunctival hyperaemia06.04.01.0040.018233%Not Available
Lymphatic disorder01.09.01.003--Not Available
Foetor hepaticus07.01.06.026; 09.01.05.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Transaminases increased13.03.01.015--Not Available
Cerebral disorder17.02.10.0170.012155%Not Available
Body fat disorder14.08.04.012--Not Available
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages